Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

This publication has 20 references indexed in Scilit:

• Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
  New England Journal of Medicine, 2007
• Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
  New England Journal of Medicine, 2007
• Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
  The Lancet, 2007
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia
  Obstetrics & Gynecology, 2006
• Detection of specific human papillomavirus types in paraffin‐embedded sections of cervical carcinomas
  Journal of Medical Virology, 2005
• Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18
  Clinical and Vaccine Immunology, 2005
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Efficacy and other milestones for human papillomavirus vaccine introduction
  Vaccine, 2004
• Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
  New England Journal of Medicine, 2003